Arcutis Biotherapeutics (ARQT) EBIT (2019 - 2026)

Arcutis Biotherapeutics' EBIT history runs 8 years deep, the most recent figure standing at -$9.1 million for Q1 2026.

• In Q1 2026, EBIT rose 62.95% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at $3.2 million (up 102.65% YoY), while the FY2025 annual figure was -$12.2 million, up 90.48% from the prior year.
• EBIT for Q1 2026 stood at -$9.1 million, down from $18.4 million in the prior quarter.
• The five-year high for EBIT was $18.4 million in Q4 2025, with the low at -$104.7 million in Q3 2022.
• The 5-year median for EBIT is -$39.1 million (2024), against an average of -$40.7 million.
• The sharpest annual moves came in 2022 and 2025: EBIT sank 83.52% in 2022, then surged 340.92% in 2025.
• Arcutis Biotherapeutics' EBIT stood at -$68.4 million in 2022, then advanced by 10.6% to -$61.2 million in 2023, then surged by 87.52% to -$7.6 million in 2024, then soared by 340.92% to $18.4 million in 2025, then plunged by 149.43% to -$9.1 million in 2026.
• Business Quant data shows ARQT's EBIT at -$9.1 million in Q1 2026, $18.4 million in Q4 2025, and $8.5 million in Q3 2025.